Investigational drug for treatment of advanced Non-Small Cell Lung Cancer

Trial ID:

IRB-22-8005

Michael P. Kosty, M.D.

This study will test the safety of an investigational oral drug, BBP-398, combined with an FDA approved dose of Nivolumab. The purpose of this Phase I study is to find a safe dose range of BBP-398 that can be given to patients with non-small cell lung cancer.

Inclusion Criteria

*Be 18 years or older
*Have documentation of a KRAS mutation
*Be willing to record daily intake of study drug in diary
*Be able to swallow oral medication

Contact Info:

• Clinical Research Services
• CRSLeadership@scrippshealth.org